GT
38
2
HPE
40
15
MMM
54
-2
CHRW
65
3
PG
64
-2
STX
50
-2
HRL
42
-2
DVN
44
-11
AON
75
2
ADT
66
-2
ESS
51
-19
ABT
63
-2
DFS
53
-24
NWS
64
-5
PM
60
-8
NVDA
52
-2
BAC
60
-3
CMCSA
53
-10
SYY
48
3
COF
62
-10
GT
38
2
HPE
40
15
MMM
54
-2
CHRW
65
3
PG
64
-2
STX
50
-2
HRL
42
-2
DVN
44
-11
AON
75
2
ADT
66
-2
ESS
51
-19
ABT
63
-2
DFS
53
-24
NWS
64
-5
PM
60
-8
NVDA
52
-2
BAC
60
-3
CMCSA
53
-10
SYY
48
3
COF
62
-10
Financhill
Back

Fulcrum Therapeutics 10K Form

Sell
11

FULC
Fulcrum Therapeutics

Last Price:
$3.15
Seasonality Move:
-17.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive FULC News And Ratings

See the #1 stock for the next 7 days that we like better than FULC

FULC Financial Statistics

Sales & Book Value

Annual Sales: $80M
Cash Flow: $-17M
Price / Cash Flow: 0
Annual Sales: $4.50
Price / Book: 0.67

Profitability

EPS (TTM): -0.22000
Net Income (TTM): $-9.7M
Gross Margin: --
Return on Equity: -8.07%
Return on Assets: -7.42%

Fulcrum Therapeutics Earnings Forecast

Key Fulcrum Therapeutics Financial Ratios

  • The Research & Development expenses have been 79.23% of Revenue.
  • The Net Earning history of FULC is -12.16% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 5 years.

Fulcrum Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: FULC
CUSIP: 359616
Website: fulcrumtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 22.07
Quick Ratio: 21.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FULC Technical Analysis vs Fundamental Analysis

Sell
11
Fulcrum Therapeutics (FULC) is a Sell

Is Fulcrum Therapeutics a Buy or a Sell?